Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**alprazolam + choline** is a combination drug kit consisting of alprazolam, a triazolobenzodiazepine benzodiazepine used primarily for the management of anxiety disorders, and choline, an essential nutrient serving as a precursor for acetylcholine biosynthesis. Alprazolam acts by binding to and positively modulating the gamma-aminobutyric acid (GABA) type-A receptor in the central nervous system, resulting in decreased neuronal excitability and anxiolytic/sedative effects[1][2][4][5]. Choline supports nerve conduction by serving as a precursor for acetylcholine, a neurotransmitter involved in memory, muscle control, and various brain functions[7]. The kit is formulated for oral administration and is indicated for anxiety disorders, where the combination may be intended to augment neurological health, though specific combination benefits beyond standard alprazolam are less established[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alprazolam + choline.